Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Fourth quarter product volume was approximately 2600 tests and product revenue was $3.7 million, up 13% year-over-year as the team did a tremendous job eliminating the patient impact of the supplier issues Marc mentioned |
| You can see that we've got a real opportunity to grow outside the US and really demonstrate that the model that we've adopted works than there has been so successful for us with the genome |
| And so I think when it comes down to it today we're in a great position |
| Over the course of 2023, we grew revenue 22% and generated $44 million in cash from operations to deliver our second consecutive year of positive cash flow |
| This is a significant proof point that our philosophy to drive cash generation, while investing in our strategic growth drivers is paying off, and we expect to achieve positive cash flow going forward |
| I am extremely proud of our strong financial profile, allowing us to further expand the impact we are having on patients' lives |
| We had some smaller managed care wins over the course of the back half of last year that really that really help us help us be confident that we'll be able to maintain ASP plus or minus a bit as we see any given quarter |
| This is driven by broad sets of genomic and clinical data deep bioinformatic and AI capabilities, a powerful evidence generation engine, which ultimately drives guideline inclusion and durable reimbursement for our tests as well as proven commercial excellence |
| So we feel great about the work the team has done both on the managed care and the billing side and collection side |
| And so we do have a very good story on the on the Decipher ASP |
| These tenants will allow Veracyte to continue to build a strong foundation for growth, while achieving our vision of transforming cancer care for patients all over the world |
| The benefit of having more and more menu available for our reps as they go out and they got this fantastic relationships with the urologists from large group practices all the way down to the community being able to offer the patients who are dealing with bladder cancer, which is a terrible prognosis in many cases and having something to offer and to enable to determine whether or not their treatment has been and has been, or is being effective, it will be incredibly meaningful |
| and AI to our world-class platform and driving revenue growth with discipline and a focus on profitability and continued positive cash generation |
| But I think the most important thing to know is, we are very confident in our ability to penetrate both of these markets up to the 80% level |
| And so time after time, we're creating new opportunities to engage with physicians and convince even more of them to use Afirma more often in more cases, and so we're gaining wins in terms of both existing accounts and new accounts |
| Extensive publications behind our tests can benefit us outside the US as well |
| So one of the great benefits of the platform that we've got the large amounts of data that we generate on is that we can that is extensible across other indications as well |
| And so incredibly rich data, the test performs extremely well |
| And then a great performance that results in, as we believe, better outcomes for patients |
| These launches and enhancements led to increased popularity and adoption of Afirma over the course of 2023, which represented a record growth year for a product which launched more than a dozen years ago |
| I am excited about the momentum we have heading into 2024 and our commitment to executing on our strategic priorities over the course of the year |
| Testing revenue during the quarter was $90.4 million, an increase of 29% year-over-year, driven by higher than expected Afirma volume, Decipher growth and strong prior period cash collections |
| Second, engaging with MolDX on that draft LCD to cover the decipher patients who could also benefit from insights provided by Afirma and lastly, scientific engagement empowered by GRID and an enhanced customer experience to ensure that we maintain and grow our community of dedicated physicians |
| This proven approach will enable our long-term growth across three vectors Global Expansion, Solving New Cancer Challenges and with the acquisition of C2i Genomics earlier this month serving more of the patient care journey |
| Q4 was another record quarter with $98.2 million in revenue, an increase of 22% over the prior year, higher than our pre-announcement due to the finalization of cash collections which benefited ASP |
| I'm excited about our trajectory and even more by the impact we are having on physicians and their patients |
| Testing gross margin was 73%, up 90 basis points compared to the prior year, benefiting from higher lead volume and over $4 million of out-of-period collections |
| So, very excited about that |
| So as you can see we ended a very strong year in 2023 and we set ourselves up well for continued growth in 2024 and beyond |
| I'm pleased to share that 2023 was a record year for Veracyte |
| Statement |
|---|
| Biopharmaceutical and other revenue was $4.1 million in line with our expectations and down 39% year-over-year, given overall spending constraints across the industry |
| Biopharmaceutical and other gross margin was 15%, down year-over-year due to lower fixed cost absorption |
| Moving to the first quarter, we are forecasting a sequential decline in total revenue given the impact of cash collections in the fourth quarter and typical seasonality |
| We have significant prior period collections as a headwind |
| I think that that's definitely a concern from the patient perspective |
| And Afirma will be bringing -- will be below the average of the two |
| This reflects year-over-year testing and product revenue growth of 13% to 15% and a decline of approximately 50% in biopharma and other revenue as we have not seen evidence yet of an improvement in the market |
| And so we are expecting it to be sequentially down quarter for Afirma maybe even a little more than we had seen in prior years given some of the weather impacts so far year-to-date and Decipher we are expecting to grow |
| And while we are -- have significant out-of-period headwind from prior periods -- significant |
| We recorded a GAAP net loss of $28.3 million which included $32 million associated with the impairment of Helio Dx biopharmaceutical intangible assets; $7.6 million of stock-based compensation; and $6.3 million of depreciation and amortization |
| Rebecca Chambers And Sung Ji, I apologize |
| One of one cause of that damage is of course smoking |
| But what we read and it had relatively low penetration and we didn't particularly drive that commercially |
| So, as soon as we can get our Decipher product launched on PCR which we are planning to do in end of 2025, I think are our expectations for the adoption now are a little bit more optimistic than they otherwise would be had we have to go and create a market from now or level of interest from scratch |
| And so the reason why I go back throughout all of that history is you know the ASP for Afirma at this point in time based on those resolutions is quite elevated |
Please consider a small donation if you think this website provides you with relevant information